The aptamer-siRNA conjugates: reprogramming T cells for cancer therapy.
作者信息
Sakib Hossain Dewan Md, Duttagupta Priyanka, Kortylewski Marcin
机构信息
Department of Cancer Immunotherapeutics & Tumor Immunology, Beckman Research Institute at City of Hope, Duarte, CA 91010, USA.
出版信息
Ther Deliv. 2015 Jan;6(1):1-4. doi: 10.4155/tde.14.92.
Abstract
摘要
相似文献
1
The aptamer-siRNA conjugates: reprogramming T cells for cancer therapy.适体-小干扰RNA偶联物：重编程T细胞用于癌症治疗
Ther Deliv. 2015 Jan;6(1):1-4. doi: 10.4155/tde.14.92.
2
CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells.CTLA4适配体将STAT3小干扰RNA递送至肿瘤相关T细胞和恶性T细胞。
J Clin Invest. 2014 Jul;124(7):2977-87. doi: 10.1172/JCI73174. Epub 2014 Jun 2.
3
[Advance in the study of targeting delivery system for siRNA mediated by aptamers].[适体介导的siRNA靶向递送系统的研究进展]
Yao Xue Xue Bao. 2012 Jul;47(7):850-5.
4
Smart ligand: aptamer-mediated targeted delivery of chemotherapeutic drugs and siRNA for cancer therapy.智能配体：适体介导的化疗药物和 siRNA 的靶向递药用于癌症治疗。
J Control Release. 2013 Oct 28;171(2):152-62. doi: 10.1016/j.jconrel.2013.06.006. Epub 2013 Jun 15.
5
Therapy. Aptamer-lipid nanoparticle conjugates for RNAi in bone.治疗。用于骨组织RNA干扰的适体-脂质纳米颗粒缀合物。
Nat Rev Endocrinol. 2015 Apr;11(4):194. doi: 10.1038/nrendo.2015.18. Epub 2015 Feb 24.
6
Reducing Toxicity of Immune Therapy Using Aptamer-Targeted Drug Delivery.利用适体靶向药物递送降低免疫治疗的毒性。
Cancer Immunol Res. 2015 Nov;3(11):1195-200. doi: 10.1158/2326-6066.CIR-15-0194.
7
Intracellular delivery of RNA-based therapeutics using aptamers.使用适配体进行基于RNA的治疗药物的细胞内递送。
Ther Deliv. 2010 Dec;1(6):849-61. doi: 10.4155/tde.10.61.
8
Ctla-4 blockade plus adoptive T-cell transfer promotes optimal melanoma immunity in mice.抗细胞毒性T淋巴细胞相关蛋白4（Ctla-4）阻断疗法联合过继性T细胞转移可促进小鼠黑色素瘤免疫达到最佳状态。
J Immunother. 2015 Feb-Mar;38(2):54-61. doi: 10.1097/CJI.0000000000000064.
9
Multivalent comb-type aptamer-siRNA conjugates for efficient and selective intracellular delivery.用于高效和选择性细胞内递送的多价梳型适配体-siRNA缀合物
Chem Commun (Camb). 2014 Jun 28;50(51):6765-7. doi: 10.1039/c4cc01620c.
10
Cell-specific RNA aptamer against human CCR5 specifically targets HIV-1 susceptible cells and inhibits HIV-1 infectivity.针对人类CCR5的细胞特异性RNA适配体特异性靶向HIV-1易感细胞并抑制HIV-1感染性。
Chem Biol. 2015 Mar 19;22(3):379-90. doi: 10.1016/j.chembiol.2015.01.005. Epub 2015 Mar 5.
引用本文的文献
1
Targeting STAT3 in tumor-associated antigen-presenting cells as a strategy for kidney and bladder cancer immunotherapy.针对肿瘤相关抗原呈递细胞中的 STAT3 作为肾脏和膀胱癌免疫治疗的一种策略。
Front Immunol. 2024 Jan 8;14:1274781. doi: 10.3389/fimmu.2023.1274781. eCollection 2023.
2
Immunotherapy for breast cancer using EpCAM aptamer tumor-targeted gene knockdown.使用 EpCAM 适体肿瘤靶向基因敲低的乳腺癌免疫治疗。
Proc Natl Acad Sci U S A. 2021 Mar 2;118(9). doi: 10.1073/pnas.2022830118.
3
GapmeR cellular internalization by macropinocytosis induces sequence-specific gene silencing in human primary T-cells.通过巨胞饮作用将 GapmeR 细胞内化诱导人原代 T 细胞中的序列特异性基因沉默。
Sci Rep. 2016 Nov 24;6:37721. doi: 10.1038/srep37721.
4
4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity.4-1BB激动剂：肿瘤免疫的多能增强剂。
Front Oncol. 2015 Jun 8;5:117. doi: 10.3389/fonc.2015.00117. eCollection 2015.
本文引用的文献
1
Non-viral vectors for gene-based therapy.基于基因治疗的非病毒载体。
Nat Rev Genet. 2014 Aug;15(8):541-55. doi: 10.1038/nrg3763. Epub 2014 Jul 15.
2
Cell-type-specific, Aptamer-functionalized Agents for Targeted Disease Therapy.细胞类型特异性，适体功能化试剂用于靶向疾病治疗。
Mol Ther Nucleic Acids. 2014 Jun 17;3(6):e169. doi: 10.1038/mtna.2014.21.
3
CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells.CTLA4适配体将STAT3小干扰RNA递送至肿瘤相关T细胞和恶性T细胞。
J Clin Invest. 2014 Jul;124(7):2977-87. doi: 10.1172/JCI73174. Epub 2014 Jun 2.
4
Immune checkpoint inhibitors: making immunotherapy a reality for the treatment of lung cancer.免疫检查点抑制剂：使免疫疗法成为治疗肺癌的现实。
Cancer Immunol Res. 2013 Aug;1(2):85-91. doi: 10.1158/2326-6066.CIR-13-0078. Epub 2013 Jul 22.
5
Retracted: FoxP3 acts as a cotranscription factor with STAT3 in tumor-induced regulatory T cells.撤回：FoxP3 在肿瘤诱导的调节性 T 细胞中与 STAT3 作为共转录因子发挥作用。
Immunity. 2013 Dec 12;39(6):1057-69. doi: 10.1016/j.immuni.2013.11.005. Epub 2013 Dec 5.
6
Current progress on aptamer-targeted oligonucleotide therapeutics.适体靶向寡核苷酸疗法的当前进展。
Ther Deliv. 2013 Dec;4(12):1527-46. doi: 10.4155/tde.13.118.
7
Aptamer-targeted inhibition of mTOR in T cells enhances antitumor immunity.T 细胞中 mTOR 的适体靶向抑制增强了抗肿瘤免疫。
J Clin Invest. 2014 Jan;124(1):188-97. doi: 10.1172/JCI69856.
8
Intracellular processing of immunostimulatory CpG-siRNA: Toll-like receptor 9 facilitates siRNA dicing and endosomal escape.免疫刺激型 CpG-siRNA 的细胞内加工： toll 样受体 9 促进 siRNA 的切割和内体逃逸。
J Control Release. 2013 Sep 28;170(3):307-15. doi: 10.1016/j.jconrel.2013.06.007. Epub 2013 Jun 15.
9
Molecular mechanisms of T cell co-stimulation and co-inhibition.T 细胞共刺激和共抑制的分子机制。
Nat Rev Immunol. 2013 Apr;13(4):227-42. doi: 10.1038/nri3405. Epub 2013 Mar 8.
10
Requirements of transcription factor Smad-dependent and -independent TGF-β signaling to control discrete T-cell functions.转录因子 Smad 依赖性和非依赖性 TGF-β 信号传导控制离散 T 细胞功能的要求。
Proc Natl Acad Sci U S A. 2012 Jan 17;109(3):905-10. doi: 10.1073/pnas.1108352109. Epub 2012 Jan 4.
Zotero 插件